Cargando…

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

SIMPLE SUMMARY: Glioblastoma (GBM) is the deadliest primary central nervous system (CNS) cancer in adults despite aggressive treatment. Once progressed, the prognosis is very poor and the effective traditional medicine treatment options are limited, so the management of recurrent glioblastoma (rGBM)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xudong, Zhao, Zihui, Dai, Wufei, Liao, Kuo, Sun, Qi, Chen, Dongjiang, Pan, Xingxin, Feng, Lishuang, Ding, Ying, Wei, Shiyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486426/ https://www.ncbi.nlm.nih.gov/pubmed/37686584 http://dx.doi.org/10.3390/cancers15174308

Ejemplares similares

The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma
por: Zhang, Lingyun, et al.
Publicado: (2023)

Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
por: Olivet, Meagan Mandabach, et al.
Publicado: (2023)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects
por: Wang, Xin, et al.
Publicado: (2021)

Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
por: Hwang, Sohyun, et al.
Publicado: (2023)

Genomic alterations dissection revealed MUC4 mutation as a potential driver in lung adenocarcinoma local recurrence
por: Yuan, Chongze, et al.
Publicado: (2023)

Glioblastoma recurrence correlates with NLGN3 levels
por: Liu, Rui, et al.
Publicado: (2018)

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
por: Li, Yan, et al.
Publicado: (2021)

Immunotherapy Resistance in Glioblastoma
por: Wang, Elaina J., et al.
Publicado: (2021)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
por: Hasan, Shaakir, et al.
Publicado: (2015)

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
por: Gromeier, Matthias, et al.
Publicado: (2021)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development
por: Majc, Bernarda, et al.
Publicado: (2021)

Current Studies of Immunotherapy on Glioblastoma
por: Agrawal, Neena Stephanie, et al.
Publicado: (2014)

Advances in immunotherapy for the treatment of glioblastoma
por: Tivnan, Amanda, et al.
Publicado: (2016)

Virus-Based Immunotherapy of Glioblastoma
por: Martikainen, Miika, et al.
Publicado: (2019)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Biomarkers for immunotherapy for treatment of glioblastoma
por: Lynes, John P, et al.
Publicado: (2020)

Current Immunotherapies for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2021)

Putting Proteomics Into Immunotherapy for Glioblastoma
por: Chen, Liangyu, et al.
Publicado: (2021)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Current Advances in Immunotherapy for Glioblastoma
por: Mende, Abigail L., et al.
Publicado: (2021)

Advances in Immunotherapy for Adult Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2021)

Next Steps for Immunotherapy in Glioblastoma
por: Cao, Toni Q., et al.
Publicado: (2022)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Metabolic Barriers to Glioblastoma Immunotherapy
por: Choudhary, Nikita, et al.
Publicado: (2023)

Immunotherapy: Reshape the Tumor Immune Microenvironment
por: LV, Bingzhe, et al.
Publicado: (2022)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

LCAT: an isoform-sensitive error correction for transcriptome sequencing long reads
por: Zhu, Wufei, et al.
Publicado: (2023)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach
por: Coleman, Niamh, et al.
Publicado: (2018)

Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside
por: Li, Yutao, et al.
Publicado: (2022)

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
por: Gardam, Bryan, et al.
Publicado: (2023)

Immunocompetent murine models for the study of glioblastoma immunotherapy
por: Oh, Taemin, et al.
Publicado: (2014)

Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
por: Eoli, Marica, et al.
Publicado: (2019)

Overview of Cellular Immunotherapy for Patients with Glioblastoma
por: Vauleon, Elodie, et al.
Publicado: (2010)

Advances in NKT cell Immunotherapy for Glioblastoma
por: Pyaram, Kalyani, et al.
Publicado: (2018)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Why is immunotherapy for glioblastoma “Lag”-ging
por: Mathios, Dimitrios, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tribajvlsl3q18tdv9leivdd2u